{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:52Z","timestamp":1791357232998,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007684","name":"Asahi Glass Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12035-017-0465-y","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T19:25:38Z","timestamp":1489433138000},"page":"2214-2226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation"],"prefix":"10.1007","volume":"55","author":[{"given":"Buranee","family":"Kanchanatawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunee","family":"Sirivichayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Geffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"465_CR1","doi-asserted-by":"crossref","unstructured":"Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G, Maes M (2017) Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic and quinolinic acid. Mol Neurobiol","DOI":"10.1007\/s12035-017-0417-6"},{"key":"465_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pnpbp.2012.06.014","volume":"42","author":"G Anderson","year":"2013","unstructured":"Anderson G, Maes M (2013) Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuro-Psychopharmacol Biol Psychiatry 42:5\u201319","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"465_CR3","unstructured":"Morris G, Berk M, Carvalho A, Caso JR, Sanz Y, Walder K, Maes M (2016) The role of the microbial metabolites including tryptophan catabolites and short chain fatty acids in the pathophysiology of immune-inflammatory and neuroimmune disease. Mol Neurobiol 27"},{"key":"465_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","volume":"45","author":"RS Smith","year":"1995","unstructured":"Smith RS, Maes M (1995) The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 45:135\u2013141","journal-title":"Med Hypotheses"},{"key":"465_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2015.01.026","volume":"164","author":"C Noto","year":"2015","unstructured":"Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, Cordeiro Q, Belangero SI et al (2015) Effects of depression on the cytokine profile in drug na\u00efve first-episode psychosis. Schizophr Res 164:53\u201358","journal-title":"Schizophr Res"},{"key":"465_CR6","unstructured":"Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Cordeiro Q, Bressan RA, Gadelha A, Brietzke E, Belangero SI, Maes M (2015) Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic na\u00efve first episode psychosis. Mol Neurobiol Oct 22"},{"key":"465_CR7","first-page":"1","volume":"27","author":"C Noto","year":"2015","unstructured":"Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E (2015) High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 27:1\u20138","journal-title":"World J Biol Psychiatry"},{"key":"465_CR8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","volume":"74","author":"J Flatow","year":"2013","unstructured":"Flatow J, Buckley P, Miller BJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 74:400\u2013409","journal-title":"Biol Psychiatry"},{"key":"465_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.3","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia. bipolar disorder and depression Mol Psychiatry. doi: 10.1038\/mp.2016.3","journal-title":"bipolar disorder and depression Mol Psychiatry"},{"key":"465_CR10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1471-4159.2002.00955.x","volume":"82","author":"T Kita","year":"2002","unstructured":"Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. J Neurochem 82:258\u2013268","journal-title":"J Neurochem"},{"key":"465_CR11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/0004867414533012","volume":"48","author":"J Davis","year":"2014","unstructured":"Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014) Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry 48:512\u2013529","journal-title":"Aust N Z J Psychiatry"},{"key":"465_CR12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neubiorev.2016.03.017","volume":"65","author":"J Davis","year":"2016","unstructured":"Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J et al (2016) A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev 65:185\u2013194","journal-title":"Neurosci Biobehav Rev"},{"key":"465_CR13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","volume":"145","author":"WT Carpenter Jr","year":"1988","unstructured":"Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578\u2013583","journal-title":"Am J Psychiatry"},{"key":"465_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/j.2051-5545.2008.tb00181.x","volume":"7","author":"B Kirkpatrick","year":"2008","unstructured":"Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry 7:143\u2013147","journal-title":"World Psychiatry"},{"key":"465_CR15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/schbul\/sbu163","volume":"41","author":"AO Ahmed","year":"2015","unstructured":"Ahmed AO, Strauss GP, Buchanan RW, Kirkpatrick B, Carpenter WT (2015) Are negative symptoms dimensional or categorical? Detection and validation of deficit schizophrenia with Taxometric and latent variable mixture models. Schizophr Bull 41:879\u2013891","journal-title":"Schizophr Bull"},{"key":"465_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2012.01.030","volume":"136","author":"BA Fischer","year":"2012","unstructured":"Fischer BA, Keller WR, Arango C, Pearlson GD, McMahon RP, Meyer WA, Francis A, Kirkpatrick B et al (2012) Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res 136:51\u201354","journal-title":"Schizophr Res"},{"key":"465_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15622975.2016.1213881","volume":"30","author":"C Roomruangwong","year":"2016","unstructured":"Roomruangwong C, Kanchanatawan B, Carvalho AF, Sirivichayakul S, Duleu S, Geffard M, Maes M (2016) Body image dissatisfaction in pregnant and non-pregnant females is strongly predicted by immune activation and mucosa-derived activation of the tryptophan catabolite (TRYCAT) pathway. World J Biol Psychiatry 30:1\u201310","journal-title":"World J Biol Psychiatry"},{"key":"465_CR18","doi-asserted-by":"crossref","unstructured":"Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF,Duleu S, Geffard M, Maes M (2016) IgA\/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome. Mol Neurobiol Apr 1","DOI":"10.1007\/s12035-016-9877-3"},{"key":"465_CR19","doi-asserted-by":"crossref","unstructured":"Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M (2010) Circulating antibodies to IDO\/THO pathway metabolites in Alzheimer\u2019s disease. Int J Alzheimers Dis 15; 2010","DOI":"10.4061\/2010\/501541"},{"key":"465_CR20","doi-asserted-by":"crossref","unstructured":"Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M (2016). IgA\/IgM responses to Gram-negative bacteria are not associated with prenatal depression, but with physio-somatic symptoms and activation of the tryptophan catabolite pathway at the end of term and postnatal anxiety. CNS Neurological Disorders \u2013 Drug Targets","DOI":"10.2174\/1871527316666170407145533"},{"key":"465_CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11920-015-0574-0","volume":"17","author":"EG Severance","year":"2015","unstructured":"Severance EG, Prandovszky E, Castiglione J, Yolken RH (2015) Gastroenterology issues in schizophrenia: why the gut matters. Curr Psychiatry Rep 17:27","journal-title":"Curr Psychiatry Rep"},{"key":"465_CR22","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.4049\/jimmunol.0804116","volume":"183","author":"T Onodera","year":"2009","unstructured":"Onodera T, Jang MH, Guo Z, Yamasaki M, Hirata T, Bai Z, Tsuji NM, Nagakubo D et al (2009) Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4\/B7 and CCL22\/CCR4 interactions. J Immunol 183:5608\u20135614","journal-title":"J Immunol"},{"key":"465_CR23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/ibd.20910","volume":"15","author":"BJ Cherayil","year":"2009","unstructured":"Cherayil BJ (2009) Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 15:1391\u20131396","journal-title":"Inflamm Bowel Dis"},{"key":"465_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1741-7015-10-66","volume":"10","author":"M Maes","year":"2012","unstructured":"Maes M, Berk M, Goehler L, Song C, Anderson G, Ga\u0142ecki P, Leonard B (2012) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10:66","journal-title":"BMC Med"},{"key":"465_CR25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","volume":"89","author":"M Maes","year":"1994","unstructured":"Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346\u2013351","journal-title":"Acta Psychiatr Scand"},{"key":"465_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF02190412","volume":"244","author":"M Maes","year":"1995","unstructured":"Maes M, Meltzer HY, Buckley P, Bosmans E (1995) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244:325\u2013329","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"465_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(96)02915-0","volume":"66","author":"M Maes","year":"1997","unstructured":"Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharp\u00e9 S (1997) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66:1\u201311","journal-title":"Psychiatry Res"},{"key":"465_CR28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jpsychires.2012.08.016","volume":"46","author":"M Borovcanin","year":"2012","unstructured":"Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML (2012) Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res 46:1421\u20131426","journal-title":"J Psychiatr Res"},{"key":"465_CR29","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2174\/1381612033454397","volume":"9","author":"D Stahl","year":"2003","unstructured":"Stahl D, Sibrowski W (2003) Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. Curr Pharm Des 9:1871\u20131880","journal-title":"Curr Pharm Des"},{"key":"465_CR30","first-page":"615","volume":"27","author":"M Maes","year":"2006","unstructured":"Maes M, Mihaylova I, Leunis JC (2006) Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 27:615\u2013621","journal-title":"Neuro Endocrinol Lett"},{"issue":"Suppl 1","key":"465_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2249.2009.04026.x","volume":"158","author":"R Schwartz-Albiez","year":"2009","unstructured":"Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y (2009) Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 158(Suppl 1):43\u201350","journal-title":"Clin Exp Immunol"},{"key":"465_CR32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0447.2012.01908.x","volume":"127","author":"M Maes","year":"2013","unstructured":"Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2013) In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 127:344\u2013354","journal-title":"Acta Psychiatr Scand"},{"key":"465_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jad.2012.06.039","volume":"149","author":"M Maes","year":"2013","unstructured":"Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2013) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J Affect Disord 149:23\u201329","journal-title":"J Affect Disord"},{"key":"465_CR34","first-page":"577","volume":"35","author":"M Maes","year":"2014","unstructured":"Maes M, Leunis JC (2014) Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in myalgic encephalomyelitis\/chronic fatigue syndrome. Neuro Endocrinol Lett 35:577\u2013585","journal-title":"Neuro Endocrinol Lett"},{"key":"465_CR35","unstructured":"Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) Thai version: Suanprung Hospital, Department of Mental Health"},{"key":"465_CR36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","volume":"30","author":"B Kirkpatrick","year":"1989","unstructured":"Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119\u2013123","journal-title":"Psychiatry Res"},{"key":"465_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","volume":"7","author":"NC Andreasen","year":"1989","unstructured":"Andreasen NC (1989) The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 7:49\u2013758","journal-title":"Br J Psychiatry Suppl"},{"key":"465_CR38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0165-1781(86)90011-9","volume":"19","author":"SR Kay","year":"1986","unstructured":"Kay SR, Fiszbein A, Opler LA (1986) Negative Symptom Rating Scale: limitations in psychometric and research methodology. Psychiatry Res 19:169\u2013173","journal-title":"Psychiatry Res"},{"key":"465_CR39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"465_CR40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr\u00f6m KO (1991) The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire. Br J Addict 86:1119\u20131127","journal-title":"Br J Addict"},{"key":"465_CR41","first-page":"157","volume":"3","author":"CK Lim","year":"2010","unstructured":"Lim CK, Brew BJ, Sundaram G, Guillemin GJ (2010) Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int J Tryptophan Res 3:157\u2013167","journal-title":"Int J Tryptophan Res"},{"key":"465_CR42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(90)90826-W","volume":"529","author":"K Jhamandas","year":"1990","unstructured":"Jhamandas K, Boegman RJ, Beninger RJ, Bialik M (1990) Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res 529:185\u2013191","journal-title":"Brain Res"},{"key":"465_CR43","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/sj.bjp.0704613","volume":"135","author":"WM Behan","year":"2002","unstructured":"Behan WM, Stone TW (2002) Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br J Pharmacol 135:1435\u20131442","journal-title":"Br J Pharmacol"},{"key":"465_CR44","first-page":"826","volume":"28","author":"M Maes","year":"2007","unstructured":"Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E (2007) The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28:826\u2013831","journal-title":"Neuro Endocrinol Lett"},{"key":"465_CR45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4137\/IJTR.S4603","volume":"3","author":"G Anderson","year":"2010","unstructured":"Anderson G, Ojala J (2010) Alzheimer\u2019s and seizures: interleukin-18, indoleamine 2,3-dioxygenase and quinolinic acid. Int J Tryptophan Res 3:169\u2013173","journal-title":"Int J Tryptophan Res"},{"key":"465_CR46","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.164.6.3283","volume":"164","author":"MC Bosco","year":"2000","unstructured":"Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L (2000) The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and \u22121 beta in macrophages. J Immunol 164:3283\u20133291","journal-title":"J Immunol"},{"key":"465_CR47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","volume":"16","author":"N Braidy","year":"2009","unstructured":"Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16:77\u201386","journal-title":"Neurotox Res"},{"key":"465_CR48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1570159X14666151113123221","volume":"14","author":"Z Majl\u00e1th","year":"2016","unstructured":"Majl\u00e1th Z, T\u00f6r\u00f6k N, Toldi J, V\u00e9csei L (2016) Memantine and kynurenic acid: current neuropharmacological aspects. Curr Neuropharmacol 14:200\u2013209","journal-title":"Curr Neuropharmacol"},{"key":"465_CR49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","volume":"33","author":"R Lugo-Huitr\u00f3n","year":"2011","unstructured":"Lugo-Huitr\u00f3n R, Blanco-Ayala T, Ugalde-Mu\u00f1iz P, Carrillo-Mora P, Pedraza-Chaverr\u00ed J, Silva-Adaya D, Maldonado PD, Torres I et al (2011) On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 33:538\u2013547","journal-title":"Neurotoxicol Teratol"},{"key":"465_CR50","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1590\/0001-3765201520140289","volume":"87","author":"GF Rio","year":"2015","unstructured":"Rio GF, Silva BV, Martinez ST, Pinto AC (2015) Anthranilic acids from isatin: an efficient, versatile and environmentally friendly method. An Acad Bras Cienc 87:1525\u20131529","journal-title":"An Acad Bras Cienc"},{"key":"465_CR51","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/jnr.23595","volume":"93","author":"L Garc\u00eda-Lara","year":"2015","unstructured":"Garc\u00eda-Lara L, P\u00e9rez-Severiano F, Gonz\u00e1lez-Esquivel D, Elizondo G, Segovia J (2015) Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress. J Neurosci Res 93:1423\u20131433","journal-title":"J Neurosci Res"},{"key":"465_CR52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2011.08.014","volume":"133","author":"KV Trecartin","year":"2011","unstructured":"Trecartin KV, Bucci DJ (2011) Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr Res 133:156\u2013158","journal-title":"Schizophr Res"},{"key":"465_CR53","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.schres.2013.09.004","volume":"150","author":"HF Iaccarino","year":"2013","unstructured":"Iaccarino HF, Suckow RF, Xie S, Bucci DJ (2013) The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: implications for schizophrenia. Schizophr Res 150:392\u2013397","journal-title":"Schizophr Res"},{"key":"465_CR54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-5728(96)00010-0","volume":"65","author":"A Boullerne","year":"1996","unstructured":"Boullerne A, Petry KG, Geffard M (1996) Circulating antibodies directed against conjugated fatty acids in sera of patients with multiple sclerosis. J Neuroimmunol 65:75\u201381","journal-title":"J Neuroimmunol"},{"key":"465_CR55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0165-5728(95)00061-6","volume":"60","author":"AI Boullerne","year":"1995","unstructured":"Boullerne AI, Petry KG, Meynard M, Geffard M (1995) Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol 60:117\u2013124","journal-title":"J Neuroimmunol"},{"key":"465_CR56","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.pnpbp.2010.12.017","volume":"35","author":"M Maes","year":"2011","unstructured":"Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new \u201c5-HT\u201d hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35:702\u2013721","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"465_CR57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.psychres.2010.07.013","volume":"185","author":"M Lee","year":"2011","unstructured":"Lee M, Jayathilake K, Dai J, Meltzer HY (2011) Decreased plasma tryptophan and tryptophan\/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Res 185:328\u2013333","journal-title":"Psychiatry Res"},{"key":"465_CR58","doi-asserted-by":"crossref","unstructured":"Walsh MJ, Tourtellotte WW, Potvin AR (1983) Central nervous system immunoglobulin synthesis in neurological disease. Chapter 19: Neurobiology of Cerebrospinal Fluid 2. Editors: Wood, James H. (Ed.) 331\u2013368","DOI":"10.1007\/978-1-4615-9269-3_19"},{"key":"465_CR59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.2015.995639","volume":"15","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Shobassy A, Grossberg GT (2015) Safety and clinical effects of EVP-6124 in subjects with Alzheimer\u2019s disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother 15:7\u201317","journal-title":"Expert Rev Neurother"},{"key":"465_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/eb-2015-102214","volume":"19","author":"SR Marder","year":"2016","unstructured":"Marder SR (2016) Alpha-7 nicotinic agonist improves cognition in schizophrenia. Evid Based Ment Health 19:60","journal-title":"Evid Based Ment Health"},{"key":"465_CR61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.scog.2016.02.001","volume":"4","author":"MM Koola","year":"2016","unstructured":"Koola MM (2016) Kynurenine pathway and cognitive impairments in schizophrenia: pharmacogenetics of galantamine and memantine. Schizophr Res Cogn 4:4\u20139","journal-title":"Schizophr Res Cogn"},{"key":"465_CR62","doi-asserted-by":"crossref","unstructured":"Erhardt S, Schwieler L, Imbeault S, Engberg G (2016) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology","DOI":"10.1016\/j.neuropharm.2016.05.020"},{"key":"465_CR63","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jpi.12013","volume":"54","author":"A Sommansson","year":"2013","unstructured":"Sommansson A, Nylander O, Sj\u00f6blom M (2013) Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo. J Pineal Res 54:282\u2013291","journal-title":"J Pineal Res"},{"key":"465_CR64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pharmthera.2010.02.009","volume":"126","author":"RP Markus","year":"2010","unstructured":"Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS (2010) Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther 126:251\u2013262","journal-title":"Pharmacol Ther"},{"key":"465_CR65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/1871527313666140711091400","volume":"13","author":"G Anderson","year":"2014","unstructured":"Anderson G, Maes M (2014) Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 13:817\u2013827","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-017-0465-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T13:38:31Z","timestamp":1568900311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-017-0465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s12035-017-0465-y","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}